Inhaler

Investigation: FTC Demand Teva Inhaler Patents Down – What’s at Stake?

by

Washington, D.C. – The Federal Trade Commission (FTC) has initiated an inquiry into Teva Pharmaceuticals’ practices, specifically their refusal to remove around two dozen patents associated with their asthma and COPD inhalers. This investigation follows the FTC’s demand for Teva to furnish internal communications, analysis, and financial data related to the disputed patents listed in the Orange Book, a federal registry. The FTC alleges that pharmaceutical companies like Teva have been making minor alterations to …

Read more

**Asthma Inhaler Crisis** as Popular Medication Discontinued – What Options Do Parents Have Now?

by

Los Angeles, CA – Parents are facing challenges in obtaining generic versions of the popular childhood asthma inhaler, Flovent, after the branded version was discontinued in January. The manufacturer, GSK, based in London, announced the discontinuation of both branded Flovent HFA and Flovent Diskus in the U.S. market, with plans to transition to authorized generics as of Jan. 1, 2024. According to the Asthma and Allergy Foundation of America (AAFA), most insurance plans are expected …

Read more